Big data and informatics are playing an increasingly significant role in health care. The August issue of AABB News focuses on the ways in which big data are being used to improve patient and donor outcomes in transfusion medicine.
The Food and Drug Administration has issued an emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) as a treatment for patients battling COVID-19. AABB has developed a new toolkit for CCP under FDA’s EUA to assist members
COVID-19 is having a significant impact on the blood community, and latest issue of AABB News contains several articles addressing the pandemic. The "High Priority" column summarizes actions by AABB and federal agencies in response to the coronavirus,
AABB recently launched a new website to share information with the public, blood collectors and clinicians about convalescent plasma from individuals who have recovered from COVID-19 (CCP). FDA recently announced new guidelines permitting the use of CCP as an investigational treatment for patients
Due to the ongoing COVID-19 pandemic, AABB has elected to delay the effective dates of the 32nd edition of Standards for Blood Banks and Transfusion Services (BBTS) and 11th edition of Standards for Immunohematology Reference Laboratories (IRL) to July 1, 2020.
